UC.PT

Jorge A.R. Salvador (Professor Catedrático, FFUC)

Laboratório de Química Farmacêutica, Faculdade de Farmácia da Universidade de Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal

E-mail: salvador@ci.uc.pt; Tel.: +351 239488479; Fax: +351 239827126.

Jorge Salvador has a degree in Pharmaceutical Sciences, (University of Coimbra) a master’s degree in Organic & Technological Chemistry, (New University of Lisbon) and a Ph.D. in Pharmacy-Pharmaceutical Chemistry (University of Coimbra in collaboration with the University of York, U.K.). He spent one year as a Postdoc student at the University of Sussex, UK. Post-grad. (1-year certif.) Cancer Biology & Therapeutics-HICR from Harvard-Medical School, University of Harvard, USA. He has a position as Full Professor at Faculty of Pharmacy of the University of Coimbra – Portugal and is a Non-Executive Member of the Board of CHEM4PHARMA, a start-up Pharmaceutical Company located in Portugal. Group leader of the scientific group “ Medicinal Chemistry & Drug Discovery” at Center for Neuroscience and Cell Biology (CNC) at the University of Coimbra, Portugal. His research group activity has been focused on studies of new semisynthetic steroid, diterpenoid, and triterpenoid derivatives with improved antitumor activity and investigation of their mechanisms of anticancer action. In addition, the discovery of novel PARP-1 inhibitors able to reverse anticancer chemoresistance and to sensitize cancer cells to chemotherapy is another line of research. Furthermore, enzyme inhibitors able to tackle hormone-dependent cancers, such as 5alpha-reductase and CYP17 inhibitors on prostatic cancer, are pursued in the group as well as new drugs acting on the ubiquitin-proteasome system (UPS). The green pharmaceutical processes, aiming to reach target molecules in a more efficient, eco-friendly, and cheaper manner are continuously pursued in the group. Recently, he has been involved in studies on pharmacophore and structure-based drug discovery for the rational design of lead compounds inhibitors of BACE1 and Glutaminyl Cyclase for Alzheimer’s disease treatment. He has edited 2 books and published more than 100 SCI journal papers, 16 book chapters, and 10 patents (2US Patents granted). In addition, he is the author/co-author of more than 250 presentations in national and international conferences and workshops. Supervisor of 4 pos-doc students, 18 PhD students (13 concluded; 5 ongoing), and > 40 MSc students. Over the last years, he has conducted several research projects in the field of pharmaceutical/medicinal chemistry which has contributed to his significant expertise in drug discovery.

Member of evaluation committees from Fundação para a Ciência e a Tecnologia (FCT), the Portuguese Research Council, and other international funding agencies (from Poland, Belgian, France, Argentine).

2014-Member of the Board of Directors of the MedChemTrain PhD program, Univ. Coimbra.

2015-Coordinator of the Master in Medicinal Chemistry

2010-2017 Coordinator of the Master in Industrial Pharmaceutical Chemistry 

2016-Director of the Mass Spectrometry Unity, University of Coimbra, 

Editorial Advisory Board of Current Green Chemistry  

Editorial Board Member for Section "Medicinal Chemistry" in Molecules, 

Guest Editor of Frontiers in Oncology

Reviewer: Organic & Biomolecular Chemistry, Natural Product Reports, Organic Letters, Chemistry-A European Journal, Journal of Organic Chemistry, Tetrahedron, Tetrahedron Letters, European Journal of Organic Chemistry, Archiv der Pharmazie, Bioorganic Medicinal Chemistry Letters, Bioorganic Medicinal Chemistry, Heteroatom Chemistry; Australian Journal of Chemistry, Canadian Journal of Chemistry, Catalysis Letters, Catalysis Communications, Current Organic Chemistry, Journal of Organometallic Chemistry, Journal of Molecular Structure, Advanced Synthesis & Catalysis, European Journal of Medicinal Chemistry, Journal of Physical Chemistry, Steroids, Synthesis, European Journal of Pharmacology, Journal of Medicinal Chemistry, among others.

 Recent Selected publications:

• Valdeira ASC, Darvishi E, Woldemichael GM, Beutler JA, Gustafson KR, Salvador JAR. Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation. J Nat Prod. 2019 Aug 23;82(8):2094-2105. doi: 10.1021/acs.jnatprod.8b00864.
• Acúrcio RC, Scomparin A, Conniot J, Salvador JAR, Satchi-Fainaro R, Florindo HF, Guedes RC.Structure-Function Analysis of Immune Checkpoint Receptors to Guide Emerging Anticancer Immunotherapy. J Med Chem. 2018 Dec 27;61(24):10957-10975. doi: 10.1021/acs.jmedchem.8b00541
• Ana S. C. Valdeira, Daniel A. Ritt, Deborah K. Morrison, James B. McMahon, Kirk R. Gustafson and Jorge A. R. Salvador, Synthesis and Biological Evaluation of New Madecassic Acid Derivatives Targeting ERK Cascade Signaling, Frontiers in Chemistry, 28 September 2018, DOI: 10.3389/fchem.2018.00434
• Judite R. M. Coimbra, Daniela F. F. Marques, Salete J. Batista, Cláudia M. Pereira, Paula I. Moreira, Teresa C. P. Dinis, Armanda E. Santos and Jorge A. R. Salvador. Highlights in BACE1 Inhibitors for the Alzheimer’s Disease treatment. Frontiers in Chemistry (2018) 6:178. doi: 10.3389/fchem.2018.00178.
• Sandra A.C.Figueiredo, Jorge A.R. Salvador, Cortés, Marta Cascante,  Design, synthesis and biological evaluation of novel C-29 carbamate celastrol derivatives as potent and selective cytotoxic compounds, European Journal of Medicinal Chemistry, Vol139, 20 Oct 2017, Pag 836-848. DOI: 10.1016/j.ejmech.2017.08.058
• Sandra A.C.Figueiredo, Jorge A.R. Salvador, Cortés, Marta Cascante,  Novel celastrol derivatives with improved selectivity and enhanced antitumour activity: Design, synthesis and biological evaluation, European Journal of Medicinal Chemistry, Vol138, 29 Sep 2017, Pag. 422-437. DOI: 10.1016/j.ejmech.2017.06.029
• Jorge A.R. Salvador, Ana S.Leal, Ana S.Valdeira, Bruno M.F.Gonçalves, Daniela P.S.Alho, Sandra A.C.Figueiredo, Samuel M.Silvestre, Vanessa I.S.Mendes, Oleanane-, ursane-, and quinone methide friedelane-type triterpenoid derivatives: Recent advances in cancer treatment, European Journal of Medicinal Chemistry,  2017. DOI: 10.1016/j.ejmech.2017.07.013
• Salete J. Batista, Maria M.C. Silva, Elisabetta Moroni, Massimiliano Meli, Giorgio Colombo, Teresa C. P. Dinis, Jorge A. R. Salvador. Novel PARP-1 Inhibitor scaffolds disclosed by a dynamic structure-based pharmacophore approach. Plos one, (2017) 12(1): e0170846.
• Gonçalves B. M. F., Salvador J. A. R., Marín S., Cascante M. Synthesis and biological evaluation of novel asiatic acid derivatives with anticancer activity RSC Adv., 2016,6, 3967-3985. DOI: 10.1039/C5RA19120C
• Bruno M. F. Gonçalves, Diana S. M. Santos, Jorge A.R. Salvador, Marín, Marta Cascante, Design, synthesis, and biological evaluation of novel asiatic acid derivatives as potential anticancer agents, RSC Adv., 2016,6, 39296-39309. DOI: 10.1039/C6RA04597A
• Mendes V. I. S., Bartholomeusz G. A., Ayres M., Gandhi V., Salvador J. A. R. Synthesis and cytotoxic activity of novel A-ring cleaved ursolic acid derivatives in human non-small cell lung cancer cells, European Journal of Medicinal Chemistry,123, (2016) 317-331. DOI: 10.1016/j.ejmech.2016.07.045
• Gonçalves B. M. F., Jorge A.R. Salvador, S., Cascante M., Synthesis and anticancer activity of novel fluorinated asiatic acid derivatives. European Journal of Medicinal Chemistry,114, (2016), Pages 101–117. DOI: 10.1016/j.ejmech.2016.02.057
• Salvador J. A. R.; Pinto R. M. A.; Silvestre S.M., Pharmaceutical green chemistry applied to the chemical synthesis of steroid compounds. Current Green Chemistry, 2015, DOI: 10.2174/2213346101666140915212312.
• Salvador J. A. R., Carvalho J. F. S., Leitão A. J., Neves M. A. C., Silva M. M. C., Silvestre S. M., Sá e Melo, M. L. Anticancer steroids: linking natural and semi-synthetic compounds. Natural Product Reports, 2013, 30, 324-374. doi: 10.1039/C2NP20082A
• Moreira V. M., Salvador J. A. R., Simões S., Destro F., Gavioli R. Novel Oleanolic vinyl boronates: synthesis and antitumor activity. European Journal of Medicinal Chemistry, 2013, 63, 46-56. doi: 10.1016/j.ejmech.2013.01.040
• Salvador J. A. R., Moreira V. M., Gonçalves B. M. F., Leal A. S. M., Jing Y. Ursane-type pentacyclic triterpenoids as useful platforms to discover anticancer drugs. Natural Product Reports, 2012, 29, 1463-1479. doi:  10.1039/C2NP20060K.

Patents:

SALVADOR, J.A.R.; SÁ E MELO, M.L.; CAMPOS NEVES, A.S., Copper-Catalysed Allylic Oxidation Using Alkyl Hydroperoxide, US Patent, US 6,252,119 B1, 2001.

CLARK, J.H.; SALVADOR, J.A.R., Cobalt Catalysed Allylic Oxidation of Unsaturated Steroids Using Alkyl Hydroperoxide, PCT /GB01/03722, 2001.

2002   CLARK, J.H.; SALVADOR, J.A.R., Cobalt Catalysed Allylic Oxidation of Unsaturated Steroids Using Alkyl Hydroperoxide, WO 02/16391 A1, 2002.

CLARK, J.H.; SALVADOR, J.A.R., Cobalt Catalysed Allylic Oxidation of Unsaturated Steroids Using Alkyl Hydroperoxide, AU Patent, AU 7995901, 2002.

2006   SALVADOR, J.A.R.; SILVESTRE, S.M., Processo para a Oxidação Alílica de Compostos Insaturados Usando Hidroperóxido de t-Butilo e Catalisadores de Bismuto, Patente Portuguesa, PT Patent 103211B, 2006.

2008   SALVADOR, J.A.R.; SILVESTRE, S.M., Processo para a Oxidação Alílica de Compostos Insaturados, Patente Portuguesa, PT Patent 103592B, 2008.

2009   SALVADOR, J.A.R.; SILVESTRE, S.M., Processo para a Oxidação Alílica de Compostos Insaturados, Patente Portuguesa, PT Patent 104193B, 2009.

2010   SALVADOR, J.A.R.; SANTOS, R.C.; SERRATOSA, M.C., Triterpenoid Derivatives and Their Use as Antiproliferative Agents, PCT/PT2010/000021, WO 2010/134830 A1, 2010.

2011   SALVADOR, J.A.R.; SANTOS, R.C.; SERRATOSA, M.C., Derivados Triterpenóides úteis como agentes Antiproliferativos, Patente Portuguesa, PT Patent 104607B, 2011.

2015   SALVADOR, J.A.R.; SANTOS, R.C.; SERRATOSA, M.C., Triterpenoid Derivatives Useful as Antiproliferative Agents, US Patent. US. 8, 969, 395 B2, 2015.